奥卡西平单药治疗2岁以下部分性发作癫痫患儿的临床观察

目的：探讨奥卡西平口服混悬液单药治疗2岁以下婴幼儿部分性发作癫痫的临床疗效和安全性。方法：收集2岁以下婴幼儿部分性发作癫痫患儿52例，给予奥卡西平口服混悬液单药治疗，起始量为8—10mg／（kg·d），渐加量至20～40mg／（kg·d），随访6～18个月，进行自身对照开放性研究，观察其疗效及安全性。结果：应用奥卡西平口服混悬液治疗后，有效率及控制率分别为94．2％、84．6％，8例（15．4％）患儿发生腹泻、呕吐、纳差、皮疹等不良反应。结论：奥卡西平口服混悬液治疗婴幼儿部分性发作癫痫疗效显著，临床应用方便，安全性好，不良反应较少，值得临床推广应用。

Clinical Evaluation of Children under Two Years of Age with Epilepsy Partial Seizures Treated by Oxcarbazepine Monotherapy

Objective： To evaluate the efficacy and security of children under two years of age with epilepsy partial seizures treated by oxcarbazepine oral suspension monotherapy. Methods ： Fifty-two cases of children under two years of age with epilepsy partial seizures were collected. Starting dose of oxcarbazepine was from 8 - 10 mg/（ kg . d）, and added to 20 - 40 mg/（ kg . d） gradually. All patients were followed up for 6 - 18 months in the self-controlled open-label study. The efficacy and safety were evaluated. Results： After taking oxcarbazepine oral suspension monotherapy, effective rate and control rate were 94.2% and 84.6% respectively; and adverse reactions rate was 15.4%. Adverse reactions included diarrhea, vomiting, poor appetite, and skin rash. Conclusions： Oxcarbazepine oral suspension monotherapy has significant effect in children under two years of age with epilepsy partial seizures. It is easy to use, with high-performance security, and few adverse reactions.